Suchergebnisse - "Atreya, Raja"

PubPharm (21)

1

Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients : A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study

enthalten in: Inflammatory bowel diseases | 2024

von Bokemeyer, B. | Plachta-Danielzik, S. | di Giuseppe, R. | +12

2

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease : a systematic review and meta-analysis

enthalten in: BMC gastroenterology | 2022

von Peyrin-Biroulet, L. | Arkkila, P. | Armuzzi, A. | +13

3

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

enthalten in: BMC gastroenterology | 2022

von Peyrin-Biroulet, L. | Arkkila, P. | Armuzzi, A. | +13

4

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

enthalten in: BMC gastroenterology | 2022

von Peyrin-Biroulet, L. | Arkkila, P. | Armuzzi, A. | +13

5

IL-23 Blockade in Anti-TNF Refractory IBD : From Mechanisms to Clinical Reality

enthalten in: Journal of Crohn's & colitis | 2022

von Atreya, R. | Neurath, M.

6

Resolution of Crohn's disease

enthalten in: Seminars in immunopathology | 2019

von Schmitt, H. | Neufert, C. | Neurath, M. | +1

7

Anti-TNF biosimilars in Crohn's Disease : a patient-centric interdisciplinary approach

enthalten in: Expert review of gastroenterology & hepatology | 2019

von Peyrin-Biroulet, L. | Danese, S. | Cummings, F. | +4

8

Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases

enthalten in: International journal of molecular sciences | 2019

von Ruder, B. | Atreya, R. | Becker, C.

9

Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease

enthalten in: The lancet. Gastroenterology & hepatology | 2018

von Atreya, R. | Neurath, M.

10

Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2018

von Atreya, R. | Reinisch, W. | Peyrin-Biroulet, L. | +6